Experimental Immunotherapy for Eye Cancer Improves Survival

An experimental immunotherapy designed to attack melanoma improved one-year survival, as compared to historical rates, in a small trial of patients with advanced uveal melanoma, the most common primary eye cancer in adults.

As reported by Columbia Newsroom, the results were presented at the annual meeting of the Association for Research in Vision and Ophthalmology by Richard Carvajal, MD, associate professor of medicine at Columbia's Vagelos College of Physicians and Surgeons, director of experimental therapeutics at Columbia Irving Medical Center and member of the Herbert Irving Comprehensive Cancer Center. The new research tested an experimental immunotherapy, IMGgp100, which was designed to further enhance the immune system’s attack against melanoma. For the full article and video, visit Columbia Newsroom.